Please login to the form below

Not currently logged in
Email:
Password:

Neurimmune appoints chief business officer

Fabian Buller will further drive the biopharma’s growth strategy

Monoclonal antibody-focused Neurimmune has appointed Fabian Buller into the newly created role of chief business officer.

Buller joins the biopharmaceutical group’s executive team, bringing with him eight years of biotech and pharma experience.

Prior to joining Neurimmune, Buller served as director new ventures at Johnson & Johnson Innovation, as well as director of business development of Covagen.

Roger Nitsch, president and CEO of Neurimmune, said: “We are pleased that Dr Buller joins our company to further drive our growth strategy.

“Dr Buller has an impressive track record in business development and licensing transactions.

“He will play a key role in realising opportunities that will allow us to bring novel therapeutics to patients.”

2nd May 2018

From: PME

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics